FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

TITUSVILLE, N.J. (NOVEMBER 6, 2025) – Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA^® (lumateperone) as an adjunctive therapy with…